MDM2 and cancer: The majority of p53 stabilizing compounds, including 4,5-dihydroimidazoline (Nutlin) and spirooxindole-based molecules, bind to MDM2, E6 or E6AP in order to disrupt the aberrant degradation of p53 in cancers [37, 38].